19 Dec 2018
Dr. Jonathan Wingfield , Principal Scientist at AstraZeneca, discusses the development of acoustic mass spectrometry technology for high-throughput screening. Through the combination of acoustic technology from Labcyte and mass spectrometry systems from Waters, acoustic mass spectrometry provides rapid sample processing and analysis of a wide range of molecular targets, saving crucial time and reagents costs needed to screen millions of compounds within AstraZeneca’s small molecule and discovery programs.
AstraZeneca
Dr. Jonathan Wingfield is a Principal Scientist within the Screening Sciences and Sample Management function Discovery Sciences at AstraZeneca. He provides scientific leadership to his team, focusing on addressing the key questions facing early drug discovery through high quality science and innovative application of technology. His team work on projects on high-throughput mass spectrometry and intracellular surface-enhanced Raman spectroscopy in the investigation of nanomaterial interactions and the understanding of biochemical pathways and pharmacodynamics.